Medical Procedure News

RSS

IGABT effective at controlling return and spread of cervical cancer

Delivering radiotherapy directly to cancer of the cervix using 3-D imaging techniques is effective at controlling the return and spread of the disease and, in most cases, avoids the need for hysterectomies, according to research presented at the World Congress of Brachytherapy today.

11 May 2012

Biosense Webster introduces new curve visualization technology in the U.S.

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the new THERMOCOOL SF NAV irrigated ablation catheter with Curve Visualization in the United States.

11 May 2012

Sorin launches full portfolio of pacing, defibrillation and left ventricular leads

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads.

11 May 2012

Robotic system can safely assist interventional cardiologists in performing PCI

A robotic system can safely assist interventional cardiologists in performing percutaneous coronary interventions (PCI) while significantly reducing the physician's exposure to radiation and improving precision and control, according to results of the PRECISE study (CorPath Percutaneous Robotically-Enhance Coronary Intervention Study), presented today as a late-breaking clinical trial at the SCAI 2012 Scientific Sessions.

11 May 2012

BIOTRONIK receives FDA approval for new Lumax 740 ICDs and CRT devices

BIOTRONIK, a leading manufacturer of innovative medical technology, has received FDA approval of its new Lumax 740 implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds). Lumax 740 helps physicians monitor and treat their patients' arrhythmias and heart failure under ever-changing medical conditions.

11 May 2012

Prototype device would help obese patients breathe during medical procedures

The best doctors strive to relieve their patients' burdens. A physician in Houston asked Rice University students to help him do so in the most literal way. A team of bioengineering seniors built a prototype device to literally lift the weight from obese patients who, while undergoing surgical procedures, might otherwise have trouble breathing.

10 May 2012

New report provides detailed criteria for rational and timely use of cardiac catheterization

A new report issued today by the American College of Cardiology Foundation (ACCF) and the Society for Cardiovascular Angiography and Interventions (SCAI) in collaboration with a dozen other professional societies provides detailed criteria to help clinicians determine when cardiac catheterization is a reasonable option for the evaluation of patients for heart disease.

10 May 2012

Hot sauce ingredient could play a role in future of weight loss

According to research from Brigham and Women's Hospital (BWH), the ingredient that gives hot sauce its heat could play a role in the future of weight loss.

10 May 2012

Lenalidomide improves overall survival for patients with multiple myeloma

Data from the first large U.S. study assessing the effectiveness of long-term "maintenance" therapy with lenalidomide for patients with multiple myeloma show that the drug significantly improves the time to progression and overall survival for patients with this often-deadly hematologic cancer.

10 May 2012

New non-embryonic stem cell treatment for cancer and leukaemia

A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.

10 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

FDA approves St. Jude Medical’s Ellipse ICD

St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its Ellipse implantable cardioverter defibrillator (ICD).

10 May 2012

Combination of Pressure Right device and antiemetics effective in reducing PONV

Pressure Point Inc. stated in a recent press release that in a peer reviewed research article appearing in the Anesthesia & Analgesia Journal last month entitled: Use of Disposable Acupressure Device, its Pressure Right acustimulation disposable (adhesive) wrist device confirmed a positive advantage when used as part of a multimodal antiemetic regimen. The clinical effects of the Pressure Right acupressure technique in a sham-controlled study comparison demonstrated a definite impact in reducing PONV.

9 May 2012

Human Gene Therapy highlights new advances in human retinal disease

Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in several articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

9 May 2012

Toshiba introduces two new software enhancements to facilitate TAVR procedures

To better facilitate transcatheter aortic valve replacement (TAVR) procedures, Toshiba America Medical Systems, Inc. introduces two new software enhancements that complement its Infinix-i cardiovascular X-ray systems.

9 May 2012

C3BS’s C-Cath Injection Catheter receives CE Marking

The Belgian biotechnology company, Cardio3--BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has received CE Marking for its intra-myocardial C-Cath Injection Catheter.

9 May 2012

Dead skin donors come to the aid of a 92 year old with severe skin ulcers

A great grandmother is the first person in Britain to have a wound healed using skin from dead donors.

9 May 2012

Goosby calls for 'extraordinary resources' to be put into male circumcision to prevent HIV infection

Male circumcision is "a highly significant, lifetime intervention" to prevent HIV infection that deserves "extraordinary resources," U.S. Global AIDS Coordinator Ambassador Eric Goosby on Monday told a meeting of 400 army officials from 80 countries in Africa, Eastern Europe and central Asia, Agence France-Presse reports.

9 May 2012

Non-drug therapy with NeuroStar TMS improves depression symptoms and QOL

New data released today at the annual meeting of the American Psychiatric Association show that patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy achieved significant improvements in both depression symptoms and in quality of life measurements.

9 May 2012

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012